The effect of alpha1-AR antagonists for lower urinary tract symptoms in patients undergoing prostate 125I brachytherapy for prostate carcinoma
Not Applicable
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000005786
- Lead Sponsor
- Kinki University Faculty of Medicine
- Brief Summary
AUA-2011 Abstract No.2161 EAU-2012 Abstract No.732 World J Urol. 2014 Jan 17
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
Patient with allergy against Silodocin. Patient with neurogenic bladder, bladder neck constructure, urethral stenosis, vesical stone, or large bladder diverticulum. Patient with active urinary tract infection. Patient with severe renal dysfunction. Patient with severe liver disease. Patient who is considered to be inapropriate for this study by physisian.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IPSS total score
- Secondary Outcome Measures
Name Time Method Pressure flow study, I-PSS storage subscores, I-PSS voiding subscores ,QOL, OABSS, IIEF5, Uroflowmetry, PVR
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie alpha1-AR antagonist efficacy in post-brachytherapy LUTS?
How do alpha1-AR antagonists compare to 5-alpha reductase inhibitors for managing LUTS after prostate brachytherapy?
Are there specific biomarkers that predict response to alpha1-AR antagonists in prostate cancer patients undergoing brachytherapy?
What are the potential adverse events associated with alpha1-AR antagonist use in prostate brachytherapy patients and how are they managed?
What combination therapies with alpha1-AR antagonists are being explored for lower urinary tract symptoms in prostate carcinoma patients?